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Résumé en
anglais
The particular status of radiopharmaceuticals, together with the positioning of
nuclear medicine in multidisciplinary approach of oncology, lead to real difficulties
for conception, validation and granting of clinical trials which are necessary for
demonstrating clinical interest of new compounds, for diagnosis as well as for
therapeutic use. This article is a presentation of some recent clinical trials
conducted in nuclear medicine in France, showing its dynamism but also pointing
out some encountered difficulties. These experiences could lead to reflexion in
order to improve the clinical research performances, taking into account a scientific
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